{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["20(1)"],"submitter":["Diouf M"],"pubmed_abstract":["Background
Health-related quality of life (QoL) has been validated as a prognostic factor for cancer patients; however, to be used in routine practice, QoL scores must be dichotomized. Cutoff points are usually based on arbitrary percentile values. We aimed to identify optimal cutoff points for six QoL scales and to quantify their added utility in the performance of four prognostic classifications in patients with hepatocellular carcinoma (HCC).Methods
We reanalyzed data of 271 patients with advanced HCC recruited between July 2002 and October 2003 from 79 institutions in France in the CHOC trial, designed to assess the efficacy of long-acting octreotide. QoL was assessed with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core "],"journal":["The oncologist"],"pagination":["62-71"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4294602"],"repository":["biostudies-literature"],"pubmed_title":["Optimal cut points for quality of life questionnaire-core 30 (QLQ-C30) scales: utility for clinical trials and updates of prognostic systems in advanced hepatocellular carcinoma."],"pmcid":["PMC4294602"],"pubmed_authors":["Dahan L","Barbare JC","Bonnetain F","Filleron T","Bouche O","Paoletti X","Diouf M"],"additional_accession":[]},"is_claimable":false,"name":"Optimal cut points for quality of life questionnaire-core 30 (QLQ-C30) scales: utility for clinical trials and updates of prognostic systems in advanced hepatocellular carcinoma.","description":"Background
Health-related quality of life (QoL) has been validated as a prognostic factor for cancer patients; however, to be used in routine practice, QoL scores must be dichotomized. Cutoff points are usually based on arbitrary percentile values. We aimed to identify optimal cutoff points for six QoL scales and to quantify their added utility in the performance of four prognostic classifications in patients with hepatocellular carcinoma (HCC).Methods
We reanalyzed data of 271 patients with advanced HCC recruited between July 2002 and October 2003 from 79 institutions in France in the CHOC trial, designed to assess the efficacy of long-acting octreotide. QoL was assessed with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core ","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Jan","modification":"2025-05-29T21:22:19.098Z","creation":"2025-05-29T21:22:19.098Z"},"accession":"S-EPMC4294602","cross_references":{"pubmed":["25542450"],"doi":["10.1634/theoncologist.2014-0175"]}}